Bausch + Lomb Corporation operates through three primary business segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment, which generates the majority of the company's revenue, offers contact lenses, lens care solutions, and over-the-counter eye drops and vitamins under brands like Biotrue, PreserVision, and Lumify. The Pharmaceuticals segment provides proprietary and generic prescription treatments for conditions such as dry eye, glaucoma, and retinal diseases, featuring products like Miebo and Xiidra. The Surgical segment manufactures intraocular lenses, delivery systems, and phacoemulsification equipment used in cataract and vitreoretinal surgeries. Founded in 1853, the company maintains a massive global footprint with manufacturing and commercial operations worldwide. Bausch + Lomb operates as a publicly traded subsidiary of Bausch Health Companies Inc., which retained a majority stake following the company's 2022 initial public offering.
